Синдром «сухого глаза» — широко распространённое многофакторное заболевание, что обусловливает высокую актуальность поиска новых эффективных методов терапии. Новизна данной поисково-аналитической работы заключается в комплексном рассмотрении патогенеза синдрома «сухого глаза» и обосновании перспективного направления лечения с использованием биомиметиков внеклеточного матрикса роговицы. В результате проведённого анализа литературных данных установлено, что современная терапия синдрома «сухого глаза» не ограничена только простым увлажнением и должна быть направлена на восстановление гомеостаза глазной поверхности и прерывание порочного круга хронического воспаления. Кроме того, установлено, что многокомпонентные препараты на основе биомиметиков внеклеточного матрикса, в частности СФЕРО® око (АО «БИОМИР сервис», Россия), демонстрируют высокую эффективность в отношении стимуляции регенерации роговицы и являются перспективными для включения в терапевтические схемы при лечении синдрома «сухого глаза». Особое внимание уделено препаратам, одобренным Управлением по контролю за продуктами питания и лекарственными средствами США, включая циклоспорин, Xiidra® (лифитеграст 5%, Bausch & Lomb Inc., США)^[℘], Eysuvis® (лотепреднол этабонат 0,25%, Kala Pharmaceuticals, США)^[℘], Miebo® (перфторгексилоктан, Novaliq, Германия)^[℘], а также назальный спрей с варениклином Tyrvaya® (Oyster Point Pharma Inc., США)^[℘]. Настоящий научный обзор подготовлен на основе анализа отечественных и зарубежных источников за период 2015–2025 гг. и предназначен для практикующих врачей-офтальмологов, стремящихся к персонализированному подходу в лечении синдрома «сухого глаза».

[℘] Препарат не зарегистрирован на территории Российской Федерации.

dry eye diseaseextracellular matrixbiomimeticscorneal epithelial protector gelreviewсиндром сухого глазавнеклеточный матриксбиомиметикипротектор эпителия роговицы гелевыйобзор1.Britten-Jones AC, Wang MTM, Samuels I, et al. Epidemiology and risk factors of dry eye disease: considerations for clinical management. Medicina. 2024;60(9):1458. doi: 10.3390/medicina60091458 EDN: MRHHLS2.Qian L, Wei W. Identified risk factors for dry eye syndrome: A systematic review and meta-analysis. PLOS ONE. 2022;17(8):e0271267. doi: 10.1371/journal.pone.0271267 EDN: GKWXPH3.Zemanová M. Dry eyes disease. A review. Czech and Slovak Ophthalmology. 2020;77(3):107–119. doi: 10.31348/2020/294.Fan M, Hung JL, Hung SH, et al. Improvement of presbyopia, dry eye, intraocular pressure, and near vision through cassiae tea consumption. Medicina. 2024;61(1):35. doi: 10.3390/medicina610100355.Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic and Physiological Optics. 2021;41(6):1254–1266. doi: 10.1111/opo.12888 EDN: NSDMEK6.Zou Y, Li D, Gianni V, et al. Prevalence of dry eye disease among children: a systematic review and meta-analysis. BMJ Open Ophthalmology. 2025;10(1):e002014. doi: 10.1136/bmjophth-2024-002014 EDN: ISCYYS7.Pieńczykowska K, Bryl A, Mrugacz M. Link between metabolic syndrome, inflammation, and eye diseases. International Journal of Molecular Sciences. 2025;26(5):2174. doi: 10.3390/ijms26052174 EDN: ELOOON8.Ma YK, Liu YY, Zhou YF, et al. Research advances in the pathogenesis of dry eye in thyroid associated ophthalmopathy. Zhonghua Yan Ke Za Zhi. 2025;61(2):156–160. DOI: 10.3760/cma.j.cn112142-20240319-001209.Liao X, Aljufairi FMAA, Sebastian JU, et al. Investigation of lacrimal gland and extraocular muscle in thyroid eye disease patients with severe subjective dry eye disease: a multiparametric magnetic resonance imaging study. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2024;262(8):2651–2659. doi: 10.1007/s00417-024-06424-x EDN: MMZZKJ10.Liu Z, Chen D, Chen X, et al. Trehalose induces autophagy against inflammation by activating TFEB signaling pathway in human corneal epithelial cells exposed to hyperosmotic stress. Investigative Opthalmology & Visual Science. 2020;61(10):26. doi: 10.1167/iovs.61.10.26 EDN: YZTQOJ11.Amer AM, Naqvi M, Charnock C. Genomics of Staphylococcus aureus and Enterococcus faecalis isolated from the ocular surface of dry eye disease sufferers. Experimental Eye Research. 2024;248:110071. doi: 10.1016/j.exer.2024.110071 EDN: UAQYIA12.Wu M, Sun C, Shi Q, et al. Dry eye disease caused by viral infection: Past, present and future. Virulence. 2023;15(1):2289779. doi: 10.1080/21505594.2023.2289779 EDN: LSIRLJ13.Ozkan J, Majzoub ME, Coroneo M, et al. Ocular microbiome changes in dry eye disease and meibomian gland dysfunction. Experimental Eye Research. 2023;235:109615. doi: 10.1016/j.exer.2023.109615 EDN: LHXQWY14.Tatarnikova EB, Krivosheina OI. State-of-the-art etiology and pathogenesis of dry eye. Clinical Ophthalmology. 2020;20(3):128–132. doi: 10.32364/2311-7729-2020-20-3-128-132 EDN: QLLBKT15.Gokul A, Wang MTM, Craig JP. Tear lipid supplement prophylaxis against dry eye in adverse environments. Contact Lens and Anterior Eye. 2018;41(1):97–100. doi: 10.1016/j.clae.2017.09.01316.Khanal S, Tomlinson A, Pearce EI, Simmons PA. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye. Cornea. 2007;26(2):175–181. doi: 10.1097/ICO.0b013e31802b492d17.Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. European Review for Medical and Pharmacological Sciences. 2020;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801 EDN: TJCNHO18.Patil S, Sawale G, Ghuge S, Sathaye S. Quintessence of currently approved and upcoming treatments for dry eye disease. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2025;263:269–278. doi: 10.1007/s00417-024-06587-719.Rolando M, Merayo-Lloves J. Management strategies for evaporative dry eye disease and future perspective. Current Eye Research. 2022;47(6):813–823. doi: 10.1080/02713683.2022.2039205 EDN: RATFCR20.Puro DG. Role of ion channels in the functional response of conjunctival goblet cells to dry eye. American Journal of Physiology-Cell Physiology. 2018;315(2):C236–C246. doi: 10.1152/ajpcell.00077.201821.Shimazaki J. Definition and diagnostic criteria of dry eye disease: historical overview and future directions. Investigative Opthalmology & Visual Science. 2018;59(14):DES7. doi: 10.1167/iovs.17-2347522.The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92. DOI: 10.1016/s1542-0124(12)70081-223.Khatri B, Tessneer KL, Rasmussen A, et al; PRECISESADS Clinical Consortium. Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells. Nature Communications. 2022;13(1):4287. doi: 10.1038/s41467-022-30773-y EDN: YZNDGC24.Safonova TN, Zaitseva GV, Burdennyy AM, Loginov VI. Association of polymorphic markers rs7947461 of the TRIM21 gene and rs33996649 of the PTPN22 gene with the risk of developing exogenous dry eye syndrome. Russian Annals of Ophthalmology. 2021;137(5):217–223. doi: 10.17116/oftalma2021137052217 EDN: GJOOHX25.Hsu CC, Chuang HK, Hsiao YJ, et al. Predicting risks of dry eye disease development using a genome-wide polygenic risk score model. Translational Vision Science & Technology. 2024;13(5):13. doi: 10.1167/tvst.13.5.13 EDN: PTAPPD26.Labetoulle M, Benitez-del-Castillo JM, Barabino S, et al. Artificial tears: biological role of their ingredients in the management of dry eye disease. International Journal of Molecular Sciences. 2022;23(5):2434. doi: 10.3390/ijms23052434 EDN: ZXBPHR27.Augustin AJ, Spitznas M, Kaviani N, et al. Oxidative reactions in the tear fluid of patients suffering from dry eyes. Graefe’s Archive for Clinical and Experimental Ophthalmology. 1995;233(11):694–698. doi: 10.1007/bf00164671 EDN: JYZDNT28.Dogru M, Kojima T, Simsek C, Tsubota K. Potential role of oxidative stress in ocular surface inflammation and dry eye disease. Investigative Opthalmology & Visual Science. 2018;59(14):DES163. doi: 10.1167/iovs.17-2340229.Hua X, Su Z, Deng R, et al. Effects of l-carnitine, erythritol and betaine on pro-inflammatory markers in primary human corneal epithelial cells exposed to hyperosmotic stress. Current Eye Research. 2014;40(7):657–667. doi: 10.3109/02713683.2014.95777630.Liu Z, Chen D, Chen X, et al. Trehalose induces autophagy against inflammation by activating TFEB signaling pathway in human corneal epithelial cells exposed to hyperosmotic stress. Investigative Opthalmology & Visual Science. 2020;61(10):26. doi: 10.1167/iovs.61.10.26 EDN: YZTQOJ31.Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. American Journal of Ophthalmology. 2009;147(2):206–213.e3. doi: 10.1016/j.ajo.2008.08.01532.Nakamura M, Hikida M, Nakano T. Concentration and molecular weight dependency of rabbit corneal epithelial wound healing on hyaluronan. Current Eye Research. 1992;11(10):981–986. doi: 10.3109/0271368920903349633.Yang G, Espandar L, Mamalis N, Prestwich GD. A cross-linked hyaluronan gel accelerates healing of corneal epithelial abrasion and alkali burn injuries in rabbits. Veterinary Ophthalmology. 2010;13(3):144–150. doi: 10.1111/j.1463-5224.2010.00771.x34.Kojima T, Nagata T, Kudo H, et al. The effects of high molecular weight hyaluronic acid eye drop application in environmental dry eye stress model mice. International Journal of Molecular Sciences. 2020;21(10):3516. doi: 10.3390/ijms21103516 EDN: VYPZZL35.Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Medicine. 2005;11(11):1173–1179. doi: 10.1038/nm131536.Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiological Reviews. 2011;91(1):221–264. doi: 10.1152/physrev.00052.2009 EDN: OMAKTJ37.Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (Varenicline Solution) nasal spray on signs and symptoms of dry eye disease. Ophthalmology. 2022;129(4):379–387. doi: 10.1016/j.ophtha.2021.11.004 EDN: GBYSYI38.Safonova TN, Zaitseva GV, Kintyukhina NP. Evolution of dry eye disease diagnostics. Russian Annals of Ophthalmology. 2023;139(3):81–89. doi: 10.17116/oftalma202313903281 EDN: ZZUMAN39.Kaštelan S, Hat K, Tomić Z, et al. Sex differences in the lacrimal gland: implications for dry eye disease. International Journal of Molecular Sciences. 2025;26(8):3833. doi: 10.3390/ijms26083833 EDN: TGFZHC40.Li T, Tang J, Wang X, et al. Evaluation of the therapeutic effect of estrogen replacement therapy combined with autologous serum therapy in controlling severe dry eye disease in perimenopausal women. Scientific Reports. 2025;15(1):26096. doi: 10.1038/s41598-025-03638-9 EDN: KIUSQF41.Pouw AE, Greiner MA, Coussa RG, et al. Cell–matrix interactions in the eye: from cornea to choroid. Cells. 2021;10(3):687. doi: 10.3390/cells1003068742.Eckes B, Nischt R, Krieg T. Cell-matrix interactions in dermal repair and scarring. Fibrogenesis & Tissue Repair. 2010;3(1):1–11. doi: 10.1186/1755-1536-3-4 EDN: QURLNI43.Baratta RO, Schlumpf E, Buono BJD, et al. Corneal collagen as a potential therapeutic target in dry eye disease. Survey of Ophthalmology. 2022;67(1):60–67. doi: 10.1016/j.survophthal.2021.04.006 EDN: UADOKJ44.Maychuk DYu, Tarkhanova AA, Pronkin IA, et al. Ophthalmic products with extracellular matrix components. Their effectiveness in the process of corneal repair in neurotrophic, herpetic, recurrent keratitis and erosions. Fyodorov Journal of Ophthalmic Surgery. 2022;(2):91–100. doi: 10.25276/0235-4160-2022-2-91-100 EDN: UTJFNG45.Guerra M, Marques S, Gil JQ, et al. Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent. Journal of Ocular Pharmacology and Therapeutics. 2017;33(9):662–669. doi: 10.1089/jop.2017.001046.Lambiase A, Sullivan BD, Schmidt TA, et al. A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease. The Ocular Surface. 2017;15(1):77–87. doi: 10.1016/j.jtos.2016.08.00447.Sevastyanov VI, Perova NV. Multicomponent hydrogel biopolymer mimetics of the extracellular matrix in regenerative medicine technologies. Opinion Leader. 2025;(8):39–55. Available from: https://docs.yandex.ru/docs/view?tm = 1777814227&tld = ru&lang = ru&name = 69_OL_8(81)_Sferogel.pdf (In Russ.)48.Pronkin IA. A method for treating recurrent corneal epithelial defects based on a 1.5% collagen-containing corneal epithelial protector gel [dissertation]. Moscow; 2017. (In Russ.) Available from: https://mntk.ru/files/upload/dissertasiya-pronkin_stndrt.pdf?ysclid = mlzae0qky2244721964 EDN: ARHYII49.Malyshev AV, Apostolova AS, Grishchenko IV, et al. Direct results of through keratoplasty using various repair stimulants. Effektivnaya farmakoterapiya. 2023;(11):18–22. (In Russ.) doi: 10.33978/2307-3586-2023-19-11-18-22 EDN: HUDOPB50.Semakina AS. Experience of using corneal epithelium protector gel for the treatment of corneal erosion for a patient after radial keratotomy. Ophthalmology in Russia. 2022;19(2):441–443. doi: 10.18008/1816-5095-2022-2-441-443 EDN: NYHFGX51.Gololobov G, Gayvoronsky Iv, Deev RV, et al. Regenerative regeneration multiiayered corneal epithelium: biotechnological potential. Genes & Cells. 2008;3(4):55–59. EDN: KLTMQV52.Shevlyuk NN, Radchenko AV, Stadnikov AA. The structural and functional basis of physiological and reparative regeneration of corneal tissues. Journal of Anatomy and Histopathology. 2019;8(2):82–90. doi: 10.18499/2225-7357-2019-8-2-82-90 EDN: JYMDKI53.Sinel’shchikova IV, Beliaev DS, Putukhova AB, et al. Morphology and medical correction of reparative regeneration processes in corneal injury. Russian Annals of Ophthalmology. 2013;129(1):56–60. EDN: PXZRAT54.Yang JW, Lee SM, Oh KH, et al. Effects of topical chondrocyte-derived extracellular matrix treatment on corneal wound healing, following an alkali burn injury. Molecular Medicine Reports. 2014;11(1):461–467. doi: 10.3892/mmr.2014.272255.Choi KH, Choi BH, Park SR, et al. The chondrogenic differentiation of mesenchymal stem cells on an extracellular matrix scaffold derived from porcine chondrocytes. Biomaterials. 2010;31(20):5355–5365. doi: 10.1016/j.biomaterials.2010.03.053 EDN: NWKZJF56.Zeng J, Lin C, Zhang S, et al. Isolation and identification of a novel anti-dry eye peptide from tilapia skin peptides based on in silico, in vitro, and in vivo approaches. International Journal of Molecular Sciences. 2023;24(16):12772. doi: 10.3390/ijms241612772 EDN: DQZVZI57.Baratta RO, Schlumpf E, Del Buono BJ, et al. A phase 2 trial to test safety and efficacy of ST-100, a unique collagen mimetic peptide ophthalmic solution for dry eye disease. Ophthalmology Science. 2024;4(3):100451. doi: 10.1016/j.xops.2023.100451 EDN: TWXMPY